Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WD 40 COWDFC · Entity 4262 | Director | February 05, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WD 40 CO
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,898 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Purchase · Acquired 424 · Balance 6,898 F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date June 30, 2023 · Filed June 30, 2023
Section 16 reporting ended · disclosed 2023-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 89,729 |
Reported balance
Holding disclosure · report date 2023-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 89,729 |
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 112,969 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2020 Filed Feb 5, 2020 18:48 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-003710 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,215 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:48 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,739 | $162.37 | $769,469.06 |
DisclosureSEC source: 0001127602-20-003710 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.77 to 163.93. The price reported above reflects the weighted average sale price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:48 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-003710 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-001127 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,954 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,739 | $155.25 | $735,729.75 |
DisclosureSEC source: 0001127602-20-001127 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $153.53 to 155.81. The price reported above reflects the weighted average sale price. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-001127 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 01:35 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-023009 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,304 F1 · shares: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for non-elective and elective portions of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F1 · price: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for non-elective and elective portions of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F2 · balance_after: Total represents 2,304 Restricted Stock Units (Common Stock equivalents). Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 02:19 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-034310 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,693 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 02:19 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,739 | $148.94 | $705,826.66 |
DisclosureSEC source: 0001127602-19-034310 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.17 to $149.94. The price reported above reflects the weighted average sale price. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 02:19 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-19-034310 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:29 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 13,223 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-19-033651 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,223 Underlying: ResMed Common Stock · 13,223 shares Expires 2026-11-21 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2020, 2021 and 2022. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:29 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 17,548 | $146.34 | $2,567,974.32 |
DisclosureSEC source: 0001127602-19-033651 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 18:29 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 31,458 | $146.34 | $4,603,563.72 |
DisclosureSEC source: 0001127602-19-033651 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,112 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 1,731 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · derivative · entry 5 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,513 Underlying: ResMed Commmon Stock · 1,731 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,199 | $143.88 | $172,512.12 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,654 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 727 | $143.88 | $104,600.76 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,853 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 860 | $143.88 | $123,736.80 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,580 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 01:41 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 1,731 | $57.76 | $99,982.56 |
DisclosureSEC source: 0001127602-19-032680 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 117.569 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 6,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,591 F2 · kind: Gift of shares to The San Diego Foundation Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,367 | $147.85 | $645,660.95 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:16 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031075 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,414 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 20:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-030141 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,367 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 20:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,367 | $128.62 | $561,683.54 |
DisclosureSEC source: 0001127602-19-030141 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,251 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 20:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-030141 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:58 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-027901 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,734 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:58 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,367 | $138.11 | $603,126.37 |
DisclosureSEC source: 0001127602-19-027901 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,251 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:58 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-027901 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:13 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026656 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,251 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 19:12 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-026158 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,101 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 19:12 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,367 | $128.56 | $561,421.52 |
DisclosureSEC source: 0001127602-19-026158 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 19:12 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-026158 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,468 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 236 | $124.40 | $29,357.93 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.22 to 124.58. The price reported above reflects the weighted average sale price. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,131 | $123.83 | $511,529.34 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,119 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.22 to $124.16. The price reported above reflects the weighted average sale price. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:03 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-024044 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 17:46 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,835 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 17:46 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,367 | $114.01 | $497,881.67 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F2 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 17:46 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 17:46 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 239 | $114.12 | $27,274.68 |
DisclosureSEC source: 0001127602-19-020649 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,883 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 06/01/2017. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:30 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-017566 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,202 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:30 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,367 | $112.58 | $491,636.86 |
DisclosureSEC source: 0001127602-19-017566 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,122 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 03, 2019 Filed May 7, 2019 17:30 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-017566 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 119.99 shares of ResMed stock purchased on April 30, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:52 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,457 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001127602-19-014941 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 4,457 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,457 | $105.21 | $468,920.97 |
DisclosureSEC source: 0001127602-19-014941 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 20:52 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,457 | $51.25 | $228,421.25 |
DisclosureSEC source: 0001127602-19-014941 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 18:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,457 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001567619-19-006100 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,457 Underlying: ResMed Common Stock · 4,457 shares Expires 2020-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 18:59 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,457 | $103.61 | $461,789.77 |
DisclosureSEC source: 0001567619-19-006100 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 18:59 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,457 | $51.25 | $228,421.25 |
DisclosureSEC source: 0001567619-19-006100 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.